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Chikungunya virus (CHIKV) is a reemerging mosquito-borne virus that causes swift 30 
outbreaks. Major concerns are the persistent and disabling polyarthralgia in infected 31 
individuals. Here we present the results from a first-in-human trial of the candidate simian 32 
adenovirus vectored vaccine ChAdOx1 Chik, expressing the CHIKV full-length structural 33 
polyprotein (Capsid, E3, E2, 6k and E1).  34 
24 adult healthy volunteers aged 18-50 years, were recruited in a dose escalation, open-label, 35 
non-randomised and uncontrolled phase 1 trial (registry NCT03590392). Participants 36 
received a single intramuscular injection of ChAdOx1 Chik at one of the three pre-37 
established dosages and were followed-up for 6 months. The primary objective was to assess 38 
safety and tolerability of ChAdOx1 Chik. The secondary objective was to assess the humoral 39 
and cellular immunogenicity.  40 
ChAdOx1 Chik was safe at all doses tested with no serious adverse reactions reported. The 41 
vast majority of solicited adverse events were mild or moderate, and self-limiting in nature. A 42 
single dose induced IgG and T-cell responses against the CHIKV structural antigens. Broadly 43 
neutralising antibodies against the four CHIKV lineages were found in all participants and as 44 
early as 2 weeks after vaccination. In summary, ChAdOx1 Chik showed excellent safety, 45 





Since its emergence in Tanzania in 19521, and subsequent reemergence in a series of 51 
outbreaks in Kenya, the Indian Ocean (2004-2006)2 and the Americas (2013-2017)3, 52 
Chikungunya virus (CHIKV) has become a major international health concern, with both 53 
acute and long-term impacts on public health. CHIKV has been identified in over 100 54 
countries across Africa, Asia, Europe and the Americas4. 55 
CHIKV is an RNA alphavirus of the Togaviridae family that is transmitted to humans in 56 
urban settings by Aedes aegypti and Aedes albopictus mosquitoes. Both mosquito species 57 
have dispersed to all continents, with Ae. aegypti present mainly in tropical and sub-tropical 58 
regions and Ae. albopictus expanding through temperate regions5. Their rapid global 59 
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expansion accounts for the possibility of an even greater burden of chikungunya fever 60 
(CHIKF) beyond tropical regions.  61 
Swift CHIKV outbreaks have recently taken place in Europe, where the East-Central-South 62 
African (ECSA) CHIKV lineage has been transmitted by the local Ae. albopictus vector6. 63 
Examples of outbreaks occur in either, low and middle income (LMIC) or high income (HIC) 64 
countries. For instance, one of the largest recorded outbreaks occurred during 2004-2007 in 65 
islands of the Indian Ocean and India2. During this outbreak, 5,202 new CHIKV cases were 66 
reported in one month, between February and March 2005. Nevertheless, seroepidemiology 67 
studies indicated that nearly 215,000 people were actually infected within one month, 68 
corresponding to 63% of the total Grande Comore Island population, leaving 79% of the 69 
cases hospitalised or staying at home7. Nine months later, in December 2005 the outbreak 70 
had extended to the neighbouring region of Reunion Island resulting in approximately 71 
255,000 cases or 33% of the total population and an estimate of 225 deaths constituting a 72 
case-fatality rate for CHIKF of 1/1000 cases8. In Italy, an outbreak occurred in 2007, 73 
affecting 205 individuals in only two months9. Autochthonous cases of CHIKF have also 74 
been recorded in France in 2010, 2014 and 201710–12, and have spread across local 75 
populations in 1-3 months after the identification of the index case. This demonstrates the 76 
need for effective actions to control outbreaks, and highlights the impact that CHIKV 77 
preventative vaccines would have if they are able to induce effective immunity rapidly after a 78 
single vaccine dose. 79 
CHIKV infections result in a wide spectrum of clinical presentations, spanning from 80 
asymptomatic to chronic, severe and even disabling arthritis13. Infections are of major 81 
concern and have a significant economic impact. Studies have estimated 151,031 CHIKV-82 
related chronic inflammatory rheumatism DALYs (Disability Adjusted Life Years) after the 83 
2014 outbreak in the Americas, roughly twice as many as the 69,000 dengue DALYs 84 
calculated in 2004 for the same region14.  85 
We have developed a replication-deficient simian adenoviral vector from chimpanzee origin 86 
expressing the entire structural cassette polyprotein of CHIKV. ChAdOx1 Chik is a 87 
chimpanzee adenoviral vector vaccine expressing the CHIKV structural proteins: Capsid, E3, 88 
E2, 6K and E1. We have previously shown, by transmission electron microscopy, that 89 
expression of the CHIKV structural cassette in mammalian cells leads to the formation of 90 
virus-like particles (VLPs) that resemble wild-type CHIKV particles15. This suggests that 91 
vaccination with ChAdOx1 Chik can induce the formation of CHIKV VLPs, which mimic 92 
the tridimensional antigen structure of CHIKV particles released during CHIKV infections. 93 
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In pre-clinical mouse models, high levels of neutralizing antibodies have been induced upon 94 
a single, unadjuvanted ChAdOx1 Chik dose15,16, eliciting complete protection against a lethal 95 
CHIKV challenge16. ChAdOx1 vectored vaccines are currently in various stages of clinical 96 
development and have been assessed in more than 18,000 volunteers across 18 clinical trials 97 
spanning 10 diseases, including Zika (NCT04015648), Chikungunya (NCT03590392), 98 
MERS (NCT04170829, NCT04170829) and COVID-19 (NCT04324606, NCT04400838, 99 
NCT04444674, ISRCTN89951424). A consistent safe and immunogenic profile has been 100 
observed following vaccination with these ChAdOx1 vectored vaccines. Here we report 101 
safety and immunogenicity data from a first-in-human trial of the ChAdOx1 Chik candidate 102 





Study Population. 108 
Between 18 July 2018 and 18 October 2019, 24 twenty-four healthy adult subjects received a 109 
single dose of ChAdOx1 Chik at 5x109, 2.5x1010 or 5x1010 vp (Fig. 1). Baseline 110 
characteristics are summarised in Table 1.  111 
 112 
Vaccine Safety. 113 
ChAdOx1 Chik was safe at doses up to 5 x 10¹ vp with no serious adverse reactions 114 
reported. A total of 112 local and systemic solicited adverse events (AEs) were reported. The 115 
vast majority of solicited AEs were mild (79/112;, 70.54%, 95%CI 61.53-78.18) or moderate 116 
(27/112; 24.11%, 95%CI 17.13-32.8) and self-limiting in nature. All solicited AEs were 117 
completely resolved within 7 days and 94.64% of them had their onset within the first 72h 118 
post vaccination (51.79% at D0, 39.29% at D1 and 3.57% at D2). Injection site pain was the 119 
most common local AE, reported by 79.17% of participants and was predominantly mild in 120 
severity. Fatigue was the most common systemic AE followed by headache, myalgia and 121 
feverishness. Frequencies of local and systemic solicited AEs reported during the first 7 days 122 
are summarised in Table 2. Median duration of solicited AEs is summarised in Table S1. 123 
Only one serious adverse event was reported but was deemed not related with ChAdOx1 124 
Chik. 125 
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Four participants reported a short-lived temperature above 37.5°C within the first 72h post 126 
vaccination (2 in the intermediate dose group and 2 in the high dose group). The highest 127 
temperature recorded was 38°C (classed as mild). All febrile episodes resolved within 24h. 128 
The proportion of moderate and severe AEs was significantly higher in group 3 compared to 129 
group 2 (relative risk 3.643, 95%CI 1.817-7.666, p<0.001), but there were no safety concerns 130 
despite the higher reactogenicity. 131 
Unsolicited AEs in the 28 days following vaccination considered possibly, probably or 132 
definitively related with ChAdOx1 Chik were predominantly mild in nature and resolved 133 
within the follow-up period (Table S3). Unsolicited AEs of note include: Shivering/Chills (1 134 
severe at D0 and D1, resolved by D2; 1 moderate at D0, resolved by D1 and 1 mild at D1, 135 
resolved by D2; all in Group 3); Insomnia (1 severe at D2, resolved by D3 - Group 3) and 136 
Lower Back Pain (1 severe at D0, resolved by D2 - Group 2) Laboratory AEs considered at 137 
least possibly related with the study intervention were self-limiting and predominantly mild 138 
in severity (Table S3). 139 
 140 
Humoral immunogenicity. 141 
Neutralising antibody titers by PRNT50 were blindly measured from all 24 participants. All 142 
doses were highly immunogenic upon a single immunisation, reaching a 100% 143 
seroconversion rate at 14 days against representative isolates from three CHIKV lineages: 144 
Indian Ocean Lineage (IOL), West African Lineage (WAf) and Asian Lineage (As). PRNT50 145 
titers to La Réunion (IOL), 37997 (WAf) and SV-0444 (As), were significantly increased 146 
from baseline and were maintained throughout the 182 days follow-up period. PRNT50 to 147 
YO111213, from the Asian-American Lineage (AsAm), demonstrated a 100% 148 
seroconversion rate on day 28 but slightly lower seroconversion rates on days 14, 56 and 182 149 
(91.6%, 91.6% and 83.3%, respectively). By day 14, Geometric Mean Titers (GMT) between 150 
40 and 226.3 were measured across the four lineages. GMT peaked at day 28 for IOL (285.5, 151 
95% CI 161.2 - 504.3), WAf (369.7, 95% CI 217.2 - 629.3) and AsAm (71.3, 95% CI 49.6 - 152 
102.4); whereas titers peaked at day 56 for As (75.3, 95% CI 48.0 - 118.3) (Table 3 and Fig. 153 
2a). An analysis per dose group (Fig. 2b) indicated that all doses are effective at inducing 154 
broadly neutralising antibodies against all CHIKV isolates tested, with PRNT50 GMT 155 
significantly higher than baseline at almost every time point. The best neutralisation was 156 
observed against IOL and WAf, with maximum PRNT50 values of 1280, 1280 and 2560 at 157 
low, intermediate and high vaccine dosages, respectively. In comparison, maximum PRNT50 158 
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GMT for each dose group were 160, 320 and 1280 for As; 320, 640 and 320 for AsAm (Fig. 159 
S2). 160 
Broad cross-neutralising and protective IgG antibodies which recognise epitopes on the 161 
CHIKV E2 protein have been found in convalescent individuals and in animals, shortly after 162 
infection17–21. A single ChAdOx1 Chik dose induced high antibody titers against CHIKV E2 163 
protein. Geometric mean ELISA units at the peak response were 80.99 (95% CI 38.65 - 164 
169.7); 205.90 (95% CI 92.66 - 457.6) and 169.70 (95% CI 71.94 - 400.3) for the low, 165 
intermediate and high dose, respectively (Table 4). Levels of anti-E2 antibodies showed a 166 
steady increase over time, reaching maximum seroconversion on day 182: 66.66% (4/6) for 167 
the low vaccine dose, 100% (9/9) for the intermediate dose and 77.77% (7/9) for the high 168 
dose (Table 4). Compared to day 0, anti-E2 IgG antibody levels started to increase by day 14 169 
(P= 0.089), were significantly higher at day 28 (P= 0.0003) and reached maximum levels at 170 
between day 56 and 182 (P= <0.0001) following vaccination (Fig. 3a). Antibodies reached 171 
significantly higher levels than baseline as early as day 14 for the high dose group, day 28 for 172 
the intermediate dose group and day 56 for the low dose group (Fig. 3b). It was observed that 173 
the calculated cut-off threshold (mean on day 0 + 3 SDEV), was influenced by 4 participants 174 
with a relatively high ELISA background at baseline. Therefore, we decided to further 175 
validate the seronegativity of these individuals with two commercially available ELISA kits. 176 
Both anti-chikungunya virus IgG ELISA kits, from Abcam and Euroimmune, confirmed that 177 
none of the participants that had high background in our in-house ELISA were seropositive 178 
for CHIKV at baseline (data not shown).  179 
PRNT50 against CHIKV IOL showed a significant positive correlation with the measured 180 
ELISA units from all dose groups, being the intermediate dose group the most positively 181 
correlated (Spearman’s Rho=0.699 [95%CI 0.5047-0.8269]; P<0.0001) (Fig. 3c). Within the 182 
intermediate dose group, a maximum correlation between PRNT50 and ELISA units was 183 
reached at day 180 (Spearman’s Rho=0.939 [95%CI 0.5047-0.8269]; P<0.0003) (Fig. 3d). 184 
 185 
Cellular immunogenicity. 186 
Cellular immunogenicity was measured from fresh peripheral blood mononuclear cells 187 
(PBMC) by an ex vivo IFN-γ ELISpot assay, using pools of peptides spanning the structural 188 
CHIKV proteins (Capsid, E3, E2, 6k and E1) as stimuli. Total responses were quantified at 189 
days 0 (baseline), 14, 28, 56 and 182 after vaccination. At baseline, the geometric mean of 190 
IFN-γ spot forming cells (SFC) per million PBMC was 180.1 (IQR 149.9 - 216.4), across all 191 
dosage groups. ChAdOx1 Chik significantly increased the number of IFN-γ SFC, peaking at 192 
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day 14 post vaccination (1031, IQR 748.9 – 1420) and remained significantly higher than 193 
baseline throughout days 28 (541.1, IQR 411.6 - 711.13); 56 (398.2, IQR 298.6 -530.9) and 194 
182 (352.8, IQR 270.1 - 460.8) (Fig. 4a).   195 
Breadth of responses against each of the five CHIKV structural antigens was measured by an 196 
ex vivo IFN-γ ELISpot assay using pools of overlapping peptides. Responses to all structural 197 
proteins, except 6K, peaked at day 14 after vaccination (Fig. 4b). We observed the largest 198 
proportion of responses against E1 and E2, with E2 responses remaining high for a longer 199 
period as compared with the other proteins. However, the size of the proteins must be taken 200 
into consideration. While E1 and E2 have a similar size and were divided into a similar 201 
number of peptides (45 and 42, respectively), the other structural proteins are significantly 202 
smaller and had a smaller number of peptides. Capsid was the third largest protein with 26 203 
peptides, whereas E3 and 6K both had only 6 peptides each.  204 
Intracellular Cytokine Staining (ICS) by flow cytometry was carried out at baseline and at 205 
day 28 after vaccination. PBMC were stimulated with pools of peptides covering the 206 
complete CHIKV structural polypeptide, and analysed for production of IFN-γ, IL-2 or TNF-207 
α. Analysis by the individual cytokines, demonstrated that only IFN-γ producing CD4+ T-208 
cells were significantly increased from baseline. An increment on TNF-α+ and IL-2+ 209 
producing CD4+ T cells was observed in a proportion of the participants but did not reach 210 
significance. CD8+ T-cell responses did not show significant differences for any of the 3 211 





We have shown safety and an excellent immunogenicity profile by a novel CHIKV vaccine 217 
using the replication-deficient chimpanzee adenoviral vector ChAdOx1 expressing the 218 
structural proteins capsid, E3, E2, 6k and E1 from CHIKV. Our findings demonstrate that the 219 
candidate ChAdOx1 Chik vaccine given as a single dose was safe and well tolerated across 220 
all doses tested, including 5 × 109, 2.5 × 1010 and 5 × 1010 vp. Higher reactogenicity was 221 
observed at the highest dose of 5 × 1010 vp. No serious adverse reactions to ChAdOx1 Chik 222 
occurred. The majority of AEs reported were mild or moderate in severity, and all were self-223 
limiting. We observed transient cases of leucopenia, neutropenia and lymphopenia in 5, 5 and 224 
1 volunteer, respectively. Most of these were mild and resolved by day 7, one was moderate 225 
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and resolved by day 28. None of them were severe. The profile of adverse events reported 226 
here is similar to the reported for other ChAdOx1 vectored vaccines expressing different 227 
antigens22,23.  228 
CHIKV causes swift outbreaks, affecting large populations and spreading to neighbouring 229 
regions rapidly. This highlights the requirement for vaccines with capacity to rapidly 230 
stimulate immunity within days after immunisation. Nevertheless, most vaccines tested in 231 
clinical trials use prime-boost regimens, requiring several weeks to induce immune 232 
responses.  233 
Animal and epidemiological studies have shown that protection from CHIKV disease is 234 
associated with the induction of neutralising antibodies18,24–26, primarily directed against 235 
structural proteins17–19. A virus-like particle (VLP) vaccine has reported to induce 236 
neutralising antibodies 8 weeks following a homologous prime-boost vaccination27. 237 
Similarly, a measles vectored vaccine (MV-CHIK) which also requires prime boost regimens 238 
at 4- and 28-week intervals, demonstrated induction of immune responses after 8 and 32 239 
weeks, respectively28. Recently, a live attenuated vaccine (LAV) CHIKV vaccine based on an 240 
ECSA lineage has been reported to use a single dose to induce 100% homologous 241 
seroconversion at day 14 after a single administration29. Our data demonstrates that the 242 
ChAdOx1 Chik platform achieves equal levels of 100% seroconversion by PRNT50 in only 243 
14 days after a single administration, with evidence of cross protective functional antibodies 244 
against 4 distinctive CHIKV lineages. To our knowledge, only one additional vaccine 245 
candidate in clinical trials has reported broad cross-neutralising responses against isolates 246 
from the 3 CHIKV genotypes (ECSA, Asian and West African) and the Indian Ocean sub-247 
lineage30.  248 
The role of T-cell immunity in clearance of CHIKV is not well understood and controversial. 249 
Although activation of CHIKV specific CD4+ and/or CD8+ T-cells has been observed upon 250 
vaccination and natural infection31–35, some publications have rejected that they might have a 251 
protective role18,24,36. Moreover, presence of reactive cytokine producing CD4+ T-cells in the 252 
joints appear to exacerbate disease and lead into the development of arthritogenic disease37,38. 253 
IFN responses are likely not pathogenic, whereas TNF-α and Th2 cytokines might be39,40. 254 
ChAdOx1 induced a CD4+ IFN-γ+ biased cellular response towards CHIKV E1 and E2 255 
proteins but had no significant effect on CD8+ T-cells. CD8+ T-cells appear to have no 256 
protective role37 and are of limited value in normal settings; only when antibodies are missing 257 
can a protective role be seen41. 258 
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Limitations of this study include the relatively short follow-up period of six months, small 259 
sample size and an open-labelled, non-randomised, uncontrolled study design. Generalisation 260 
of the study findings is limited, as this is a first-in-human study of healthy volunteers. Further 261 
studies should be conducted in older and younger age groups, adults with comorbidities and 262 
in populations considered to be at risk of developing chronic arthritis following CHIKV 263 
infection.   264 
In conclusion, ChAdOx1 Chik was safe and well tolerated at all tested doses. A single dose 265 
showed compelling evidence of rapid stimulation of cellular responses and induction of high 266 
titers of functional antibodies with capacity to neutralise multiple CHIKV lineages. Since our 267 
platform does not require an adjuvant and shows to be immunogenic even at a low dose, 268 
ChAdOx1 Chik constitutes an attractive product for manufacturers and an affordable 269 
preventive vaccine for low-income countries. The ability to induce robust cellular and 270 
humoral immunity upon a single administration portraits ChAdOx1 Chik as a suitable 271 
candidate to limit swift outbreaks around the world. The results of this first-in-human clinical 272 
trial support clinical development progression into phase 1b and 2 trials in CHIKV-endemic 273 





Trial objectives, participants and oversight. 279 
This is a first-in-human, dose escalation, open-label, non-randomised and uncontrolled 280 
clinical study of 24 healthy male and female subjects aged 18–50 years old. The sample size 281 
was selected based on other previous phase I trials using the same vector. This sample size 282 
was able to detect significant differences in immune responses from baseline while exposing 283 
a limited number of people to an investigational medicinal product that was being used for 284 
the first time.  285 
The primary objective was to assess safety and tolerability of ChAdOx1 Chik in healthy 286 
volunteers, measured as: a) occurrence of solicited local reactogenicity signs and symptoms 287 
for 7 days following vaccination; b) occurrence of solicited systemic reactogenicity signs and 288 
symptoms for 7 days following vaccination; c) occurrence of unsolicited adverse events 289 
(AEs) for 28 days following vaccination; d) change from baseline for safety laboratory 290 
measures and; e) occurrence of serious adverse events (SAEs) during the whole study 291 
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duration. The secondary objective was to assess CHIKV structural antigen-specific humoral 292 
and cellular immune responses induced by ChAdOx1 Chik as measured by enzyme-linked 293 
immunosorbent assay (ELISA), plaque reduction neutralisation test (PRNT) and ex vivo 294 
interferon-gamma (IFN-γ) enzyme-linked immunospot (ELISpot). 295 
Eligible volunteers were recruited at the Centre for Clinical Vaccinology and Tropical 296 
Medicine, Oxford, United Kingdom (CONSORT diagram, Fig. 1). All participants were 297 
healthy adults with negative pre-vaccination tests for HIV antibodies, hepatitis B surface 298 
antigen and hepatitis C antibodies. A negative urinary pregnancy test was required at 299 
screening and immediately before enrolment for all female subjects. Screening for previous 300 
CHIKV exposure was conducted on participants with significant travel history to CHIKV 301 
endemic areas, using a commercial ELISA kit (Anti-Chikungunya Virus IgG Human ELISA 302 
Kit, Abcam ab177835) and were excluded if positive. Full details of the eligibility criteria are 303 
described in the trial protocol provided in the Supplementary Materials. 304 
The corresponding author had full access to all the data in the trial and had final 305 
responsibility for the decision to submit the manuscript for publication. All the trial data were 306 
available to all the authors. 307 
 308 
Study approvals. 309 
Written informed consent was obtained in all cases, and the trial was conducted in 310 
accordance with the principles of the Declaration of Helsinki and Good Clinical Practice 311 
(GCP). This study was approved within the UK by the Medicines and Healthcare Products 312 
Regulatory Agency (MHRA reference 21584/0394/001-0001) and the South Central Oxford 313 
A Research Ethics Committee (REC reference 18/SC/0004). Vaccine use was authorized by 314 
the Genetically Modified Organisms Safety Committee of the Oxford University Hospitals 315 
National Health Service Trust (GMSC reference number GM462.18.102). The trial is 316 
registered at www.clinicaltrials.gov (identifier: NCT03590392). The first participant was 317 
enrolled on 02 October 2018 and the last participant was enrolled on 01 April 2019.  318 
 319 
Trial procedures. 320 
ChAdOx1 Chik was administered as a single intramuscular injection into the deltoid at a low 321 
dose of 5x109 vp (group 1), intermediate dose of 2.5x1010 vp (group 2) and high dose of 5 x 322 
1010 vp (group 3). A staggered-enrolment approach was used for the first 3 participants in 323 
each group and interim safety reviews conducted prior to dose escalation (details provided in 324 
study protocol).   325 
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Blood samples were drawn and clinical assessments conducted for safety as well as 326 
immunology endpoints prior to vaccination at day 0 and subsequently at 2, 7, 14, 28, 56 and 327 
182 days following enrolment. Participants were observed in the clinic for one hour after the 328 
vaccination procedure and were asked to record any AEs using electronic diaries during the 329 
28-day follow-up period. Swelling at the injection site was objectively assessed by a member 330 
of the study team during the study visits. 331 
Expected and protocol defined local site reactions (injection site pain, warmth, redness and 332 
pruritus) and systemic symptoms (malaise, myalgia, arthralgia, fatigue, nausea, headache, 333 
feverishness and temperature) were recorded for 7 days. Unsolicited AEs were recorded for 334 
28 days and SAEs were recorded throughout the follow-up period.  335 
Severity of AEs was graded using the following criteria: (a) mild (short-lived or mild 336 
symptoms with no limitation to usual activity); (b) moderate (mild to moderate limitation in 337 
usual activity); and (c) severe (considerable limitation in activity, medication or medical 338 
attention required). Unsolicited AEs were reviewed for causality by an independent clinician 339 
and events considered possibly, probably or definitively related with the study vaccine were 340 
reported. Laboratory AEs were graded using site-specific toxicity tables which were adapted 341 
from the US Food and Drug Administration toxicity grading scale. An independent Local 342 
Safety Monitor (LSM) provided safety oversight. The relevant clinical data was recorded in a 343 
study database using OpenClinica (Enterprise Edition) v3.13.  344 
 345 
ChAdOx1 Chik Vaccine. 346 
ChAdOx1 Chik uses the replication-deficient adenovirus vector derived from the E1 E3-347 
defficient ChAdY2542 and is currently a leading vaccine platform against COVID-1943. 348 
ChAdOx1 Chik was engineered to express the full structural polyprotein genome of CHIKV 349 
that includes the Capsid, E3, E2, E1 and the 6K proteins. The synthetic gene was designed 350 
through an analysis of full-length structural polyprotein sequences from multiple CHIKV 351 
lineages. Sequences were collected from the NCBI database and aligned using Clustal Omega 352 
and a neighbour-joining tree (Juke-Cantor, 100 bootstraps). Intra- and inter-clade 353 
conservation was calculated using a sliding window approach with a sequence weighting 354 
method to enable equal representation of all lineages and variants. A synthetic gene cassette 355 
was produced by GeneArt® (ThermoFisher Scientific), which was subsequently cloned into a 356 
pMono plasmid to be driven by a CMV promoter expression15. The vaccine was 357 
manufactured to current Good Manufacturing Practice (cGMP) by the Clinical 358 
Biomanufacturing Facility (University of Oxford, Oxford, UK) in a HEK 293 cell line. The 359 
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vectored vaccine was purified and sterile filtered to generate a clinical lot at a concentration 360 
of 1.57x1011 viral particles per mL.  361 
 362 
ELISA. 363 
Total anti-CHIKV IgG was measured using a standardised in-house indirect ELISA44. To this 364 
end, 1 µg/ml of CHIKV E2 recombinant protein in phosphate buffered saline (PBS) were 365 
used to coat Nunc-immuno 96 well plates. Plates were incubated at 4°C for 18 h 366 
overnight15,45. Coated plates were washed six times with PBS-Tween followed by blocking 367 
with casein for 1 h at room temperature (RT). Serum samples were diluted at 1:100 or 1:500 368 
in casein to fit within the linear range of a standard curve prepared as indicated below, and 369 
then added to individual wells in triplicates. Plates were incubated at RT for 2 h, washed as 370 
described and then incubated at RT for 1 h with an alkaline phosphatase conjugated goat anti-371 
human IgG (gamma-chain specific, Sigma). Plates were developed by adding 4-nitrophenyl 372 
phosphate (Sigma) in diethanolamine substrate buffer (Thermo Scientific). A standard curve 373 
was prepared from a serum sample of a convalescent individual, following a 2-fold serial 374 
dilution starting at 1:100 and generating 10 standard points to which arbitrary ELISA units 375 
(EUs) were assigned.  The optical density (OD) values of the standard points were fitted to a 376 
4-parameter hyperbolic curve against the arbitrary EUs using the BioTek Gen5 v3.09 377 
software and the parameters estimated from the standard curve were used to convert 378 
absorbance values of individual test samples into EU. Each ELISA plate contained the 379 
samples in triplicates, an internal positive control at 1:1600 dilution of the standard pool in 380 
triplicates, 10 standard points in duplicates and 4 blank wells. Absorbance reading at 405 nm 381 
was performed using an ELx808 microplate reader (BioTek). The assay cut-off was 382 
determined from the analysis of the 24 pre-vaccinated (Day 0) samples of the trial volunteers. 383 
The seropositive cut-off was determined mathematically using the mean plus three standard 384 
deviations of the EU values reported for the 24 samples assayed. This value defined the 385 
threshold from which detection was feasible. A cut-off value of 51.1 EU was used as the 386 
analytical sensitivity of this assay.  387 
Two commercially available ELISA kits were used to validate seronegativity of serum 388 
samples that had a higher background in our in-house E2 ELISA at baseline. The anti-389 
chikungunya virus IgG ELISA kit from Abcam (ab177835) and the anti-chikungunya virus 390 
IgG ELISA kit from Euroimmune (EI 293a-9601G) were both performed according to 391 
manufacturer’s instructions.  392 
 393 
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Plaque Reduction Neutralisation Tests (PRNT).  394 
Induction of serum neutralising antibodies was evaluated with a plaque reduction 395 
neutralisation tests (PRNT) on monolayers of Vero-cells (Vero ATCC CCL-81) cultured in 396 
12-well plates using standard methods46,47. Neutralising antibody titers were recorded for four 397 
CHIKV lineages including the chikungunya strains CHIKV-LR (Indian Ocean Lineage, 398 
IOL), SV-0444 (Asian Lineage), 37997 (West African Lineage) and YO111213 399 
(Asian/American Lineage), all obtained from the World Reference Center for Emerging 400 
Viruses and Arboviruses at UTMB46. Titers were quantified as the highest serum dilution that 401 
inhibited plaque formation in 50% (PRNT50). Seroconversion was considered positive in 402 
samples with reciprocal titers of PRNT50 ≥10 
48. Limits of detection were between 10 and 403 
1280, and any samples without a detectable titer were listed as either 5 or 2560.  404 
 405 
ELISpot. 406 
Cellular immune responses were quantified at the selected timepoints using an ex-407 
vivo Enzyme-linked immunospot (ELISpot) for IFN-γ43,44. PBMC were stimulated with 408 
125 synthetic peptides (20mers overlapping by ten amino acids), divided into 13 peptide 409 
pools spanning the entire vaccine insert of the CHIKV structural antigens: Capsid (3 410 
pools=26 peptides), E3 (1 pool=6 peptides), E2 (4 pools=42 peptides), 6k (1 pool=6 peptides) 411 
and E1 (4 pools=45 peptides). Peptide sequences and pooling are summarised in 412 
supplementary Table S4.  Data were analysed according to a quality control standard 413 
operational procedure. The lower limit of detection for the assay was 4 spot-forming cells 414 
(SFCs) for summed responses to the 13 CHIKV structural antigen peptide pools. The 415 
following antibodies were used for ELISpot assay: anti-human IFN-y capture IgG1 mouse 416 
monoclonal Ab (dil 1:100) and anti-human IFN-y biotinylated , detection mouse IgG1 417 
monoclonal Ab (dil 1:1000). 418 
 419 
Flow cytometry. 420 
Intracellular cytokine staining for flow cytometry (ICS) was performed to quantify CD4+ and 421 
CD8+ T-cell responses to the vaccine49. Five peptide pools from the structural CHIKV 422 
cassette were used as stimuli (Table S4). Representative gating strategy is shown in Fig S1. 423 
For the stimulation and staining, the following antibodies were used: anti-human CD14 424 
eFluor450 (dil 1:100), anti-human CD19 eFluor450 (dil 1:100), anti-human CD3 AF700 (dil 425 
1:50), anti-human CD4 APC (dil 1:25), anti-human CD8a APC eFluor780 (dil 1:10), anti-426 
human IFN-y FITC (dil 1:250), anti-human TNF-a PE-Cy7 (dil 1:500), anti-human IL-2 PE 427 
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(dil 1:50), anti-human CD28 (1 μg/mL) and anti-human CD49d (Integrin alpha 4) (1 μg/mL).  428 
Samples were ran in a LSRFortessa (Becton Dickinson); FACSDiva v 8.02 (BD Biosciences) 429 




Safety endpoints are described as frequencies with their respective percentages alongside 434 
95% confidence intervals (CI). The association between the frequency of moderate or severe 435 
solicited AEs and group allocation (groups 2 and 3) is reported as relative risk with the 436 
respective 95% CI and p value (Fisher’s exact test). A Kruskal-Wallis test with Dunn’s 437 
correction for multiple tests was used to assess the CHIKV ex vivo ELISpot IFN-γ responses, 438 
whereas a two-tailed Mann-Whitney test was used for ICS data. ELISA and PRNT data were 439 
analysed by either Kruskal-Wallis test or Friedman test with Dunn’s correction for multiple 440 
parameters, as appropriate. A P value <0.05 was considered significant. Statistical analysis of 441 
safety and immunogenicity data was conducted using GraphPad Prism version 9.1 (GraphPad 442 
Software Inc., California, USA). 443 
 444 
 445 
DATA AVAILABILITY 446 
There is a restriction on the availability of the data presented on this manuscript due to the 447 
data being used to feed a patent application and because data will be linked to an ongoing 448 
Phase 1b blinded study funded by a different research award. Anonymised participant data 449 
may be available upon requests directed to the corresponding author 450 
(arturo.reyes@ndm.ox.ac.uk). Proposals will be reviewed and approved by the sponsor 451 
(CTRG- https://researchsupport.admin.ox.ac.uk/ctrg#/), principal investigator, and 452 
collaborators on the basis of scientific merit. If approved and upon signature of a data access 453 
agreement, data can be shared through a secure online platform. Data sharing may take a 454 
period of up to 6 weeks from receiving the request. All data will be made available for a 455 
minimum of 5 years from the end of the trial. The study protocol is available with this 456 
publication as part of the supplementary material. 457 
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 618 
FIGURE LEGENDS 619 
Figure 1. Trial profile. Study profile showing allocation of participants to 3 dosage groups: 620 
Group 1 low dose at 5x109 vp, Group 2 intermediate dose at 2.5x1010 vp and Group 3 high 621 
dose at 5x1010 vp. None of the 24 recruited participants were lost in follow-up. 622 
 623 
Figure 2. PRNT50 values over time. PRNT50 reciprocal titres are shown for each participant. 624 
Arrows indicate when ChAdOx1 Chik was administered. Lower limit of detection (LLOD) is 625 
5. a) Overall responses by timepoint in all trial volunteers (n = 24). Geometric means and 626 
95% CI; Kruskal-Wallis test with Dunn’s correction. b) Same data as a) but analysed by 627 
dosage groups: low dose was 5x109 vp (n = 6), intermediate (mid) dose was 2.5x1010 vp (n = 628 
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9) and high dose was 5x1010 vp (n = 9). Geometric means and 95% CI; Kruskal-Wallis test 629 
with Dunn’s correction. One day 56 sample from the low dose group was excluded from 630 
analysis due to QC failure.   631 
 632 
Figure 3. ELISA titers over time. CHIKV IgG response by standardised ELISA to E2 633 
protein in 120 serum samples of trial participants. a) Individual IgG titers over time (n =24). 634 
The dashed line represents the cut-off value for seropositivity. Geometric means and 95% CI; 635 
Friedman test with Dunn’s correction. b) Same data as a) but represented as fold-change from 636 
baseline (day 0) and analysed by dosage group: low dose was 5x109 vp (n = 6), intermediate 637 
(mid) dose was 2.5x1010 vp (n = 9) and high dose was 5x1010 vp (n = 9). Geometric means 638 
and 95% CI; Friedman test with Dunn’s correction. c) Correlation of PRNT50 and IgG ELISA 639 
by dosage group at 5 time points. Low dose, 6 participants, n = 29 (one day 56 sample was 640 
excluded due to QC failure); intermediate (mid) dose, 9 participants (n = 45) and high dose, 9 641 
participants (n = 45). Spearman correlation, two-tailed. d) Same data as c) but correlation is 642 
only shown for the 9 participants vaccinated at the intermediate (mid) dose (n = 9 per 643 
timepoint). Spearman correlation, two-tailed. 644 
 645 
Figure 4. T cell responses over time. a) Ex-vivo Enzyme-linked immunospot (ELISpot) for 646 
IFN-γ to CHIKV structural antigens measured as total responses to CHIKV peptides (sum of 647 
13 pools spanning C, E3, E2, 6K, E1). SFC per million PBMC during a 6-month follow-up 648 
period (n = 24). Median and IQR; Kruskal-Wallis test with Dunn’s correction. b) Proportion 649 
of spots contributed by C, E3, E2, 6K and E1 over time. c) Intracellular Cytokine Staining 650 
(ICS) by flow cytometry to assess CD4+ and CD8+ T-cell functionality. Percentage of 651 
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Antibodies against CHIKV E2 protein
Low dose Mid dose High dose

Table 1. Summary of participants’ baseline characteristics. 
*Mixed: White and Asian. 
Variable 
Group 1 
Low dose  
(n = 6) 
Group 2 
Intermediate dose 
(n = 9) 
Group 3 
High dose  
(n = 9) 
All Groups 
(n = 24) 
Age     
    Median 43 26 24 29 
    Range 20-45 18-41 21-43 18-45 
Sex     
    Male – n (%) 2 (33·33) 2 (22·22) 2 (22·22) 6 (25) 
    Female – n (%) 4 (66·67) 7 (77·78) 7 (77·78) 18 (75) 
Ethnicity     
    White – n (%) 6 (100) 5 (55·56) 8 (88·89) 19 (79·17) 
    Mixed* – n (%) - 1 (11·11) - 1 (4·17) 
    Latin American – n (%) - 3 (33·33) 1 (11·11) 4 (16·67) 
 
 
Table 2. Number of participants reporting local and systemic solicited AEs. 
 
 
ChAdOx1 Chik 5x109 vp 
(n = 6) 
ChAdOx1 Chik 2.5x1010 vp 
(n = 9) 
ChAdOx1 Chik 5x1010 vp 
(n = 9) 
 Any Mild Moderate Severe Any Mild Moderate Severe Any Mild Moderate Severe 
Any symptom 4 (67%) 4 (67%) 0 0 9 (100%) 6 (67%) 3 (33%) 0 9 (100%) 4 (44%) 3 (33%) 2 (22%) 
Any local symptom 3 (50%) 3 (50%) 0 0 9 (100%) 8 (89%) 1 (11%) 0 7 (78%) 5 (56%) 2 (22%) 0 
Pain 3 (50%) 3 (50%) 0 0 9 (100%) 8 (89%) 1 (11%) 0 7 (78%) 5 (56%) 2 (22%) 0 
Pruritus 0 0 0 0 0 0 0 0 0 0 0 0 
Warmth 0 0 0 0 4 (44%) 4 (44%) 0 0 3 (33%) 3 (33%) 0 0 
Swelling 0 0 0 0 0 0 0 0 0 0 0 0 
Erythema 0 0 0 0 0 0 0 0 1 (11%) 1 (11%) 0 0 
Any systemic symptom 2 (33%) 2 (33%) 0 0 9 (100%) 6 (67%) 3 (33%) 0 9 (100%) 4 (44%) 3 (33%) 2 (22%) 
Fever 0 0 0 0 2 (22%) 2 (22%) 0 0 2 (22%) 2 (22%) 0 0 
Feverishness 1 (17%) 1 (17%) 0 0 6 (67%) 3 (33%) 3 (33%) 0 7 (78%) 4 (44%) 2 (22%) 1 (11%) 
Arthralgia 0 0 0 0 3 (33%) 3 (33%) 0 0 4 (44%) 0 3 (33%) 1 (11%) 
Myalgia 1 (17%) 1 (17%) 0 0 7 (78%) 6 (67%) 1 (11%) 0 6 (67%) 2 (22%) 3 (33%) 1 (11%) 
Headache 1 (17%) 1 (17%) 0 0 7 (78%) 6 (67%) 1 (11%) 0 6 (67%) 3 (33%) 1 (11%) 2 (22%) 
Fatigue 2 (33%) 2 (33%) 0 0 5 (56%) 5 (56%) 0 0 8 (89%) 4 (44%) 4 (44%) 0 
Nausea 0 0 0 0 2 (22%) 1 (11%) 1 (11%) 0 3 (33%) 1 (11%) 2 (22%) 0 
Malaise 1 (17%) 1 (17%) 0 0 6 (67%) 6 (67%) 0 0 5 (56%) 1 (11%) 3 (33%) 1 (11%) 
 
Table 3. PRNT50 against CHIKV lineages.  
PRNT50 = serum dilution required to reduce viral plaques by 50% of the control value. Seroconversion was measured as PRNT50 values of 10 or greater. 
*One day 56 sample, from the low dose group, was excluded from analysis due to QC failure. 
 
PRNT50 
















Geometric mean titres 
(95% CI) 
Day 0 0% 5 (5.0 - 5.0) 0% 5 (5.0 - 5.0) 0% 5 (5.0 - 5.0) 0% 5 (5.0 - 5.0) 
Day 14 100% 164.7 (102.3 - 265.2) 100% 226.3 (139.9 - 365.9) 100% 47.6 (29.4 - 77.1) 91.6% 40 (25.5 - 62.6) 
Day 28 100% 285.1 (161.2 - 504.3) 100% 369.7 (217.2 - 629.3) 100% 67.3 (46.1 - 98.2) 100% 71.3 (49.6 - 102.4) 
Day 56* 100% 222.9 (143.3 - 346.6) 100% 251.4 (148.9 - 424.6) 100% 75.3 (48.0 - 118.3) 91.6% 49.4 (28.6 - 85.2) 
Day 182 100% 213.6 (126.4 - 360.8) 100% 229.7 (125.4 - 420.8) 100% 95.1 (56.2 - 161.1) 83.3% 42.4 (21.9 - 82.2) 
  
 
Table 4. CHIKV IgG response by standardised ELISA to E2 protein.  
Data are geometric mean with 95% CI. Analysis was made using Friedman with Dunn’s. Cut-off = average of days 0 + 3 SDEV. 
 
ELISA 
Low dose  
(n = 6) 
Intermediate dose  
(n = 9) 
High dose  












Geometric mean titres 
(95% CI) 
Day 0 0 (0%) 4.741 (0.806 - 27.87) 0 (0%) 4.725 (1.392 - 16.04) 0 (0%) 3.009 (1.231 - 7.354) 
Day 14 2 (33.33%) 7.475 (1.075 - 51.95) 3 (33.33%) 13.03 (4.078 - 41.66) 0 (0%) 12.14 (6.449 - 22.84) 
Day 28 1 (16.66%) 28.83 (19.10 - 43.52) 4 (44.44%) 44.51 (23.90 - 82.90) 1 (11.11%) 29.18 (21.07 - 40.42) 
Day 56 3 (50%) 41.67 (21.51 - 80.74) 6 (66.66%) 87.10 (42.56 - 178.2) 7 (77.77%) 70.02 (45.76 - 107.1) 
Day 182 4 (66.66%) 80.99 (38.65 - 169.7) 9 (100%) 205.9 (92.66 - 457.6) 7 (77.77%) 169.7 (71.94 - 400.3) 
 
 
